Citations

Showing 10 of 108094 citations.

Exposure to radon and heavy particulate pollution and incidence of brain tumors
Prasad, Rahul N. , Cioffi, Gino , Kruchtko, Carol, Trifiletti, Daniel M. , Gondi, Vinai , Brown, Paul D. , Perlow, Haley K. , Mishra, Mark V. , Chakravarti, Arnab , Ostrom, Quinn T. , Palmer, Joshua D , Cioffi, Gino , Trifiletti, Daniel M , Mishra, Mark V , Perlow, Haley K , Chakravarti, Arnab , Ostrom, Quinn T , Palmer, Joshua D. , Zaorsky, Nicholas G. , Barnholtz‐Sloan, Jill S.

Mayo Clinic

Neuro-Oncology | June 28, 2022 | Volume: 25 | Issue: 2 | Pages: 407-417

10.1093/neuonc/noac163 | PMID 35762336 Get It

Abstract Background Global incidence for brain tumors varies substantially without explanation. Studies correlating radon exposure and incidence are inconclusive. Particulate pollution has been linked to increased tumor incidence. Particulates may disrupt the blood-brain barrier allowing intracranial exposure to oncogenic radon. We investigated the relationship between exposure to residential radon, particulate pollution, and brain tumor incidence in the United States (US). Methods County-level median radon testing results and annual air quality index values were obtained and divided into tertiles. Counties without both values were excluded. Four groups of counties were generated: high particulate/high radon (high/high), high/low, low/high, and low/low. Using incidence data from the Central Brain Tumor Registry of the US (provided by CDC’s National Program of Cancer Registries and NCI’s SEER), annual age-adjusted incidence rates (AAAIRs) by group were generated by behavior. Incidence rate ratios were calculated to examine for significant differences (α = .05). Poisson regression accounting for possible confounders was conducted. Results Counties with available data included 83% of the US population. High/high exposure was significantly associated with increased AAAIR of all non-malignant tumors (up to 26% higher, including most meningiomas) even after accounting for potential confounders. An increased AAAIR was noted for all malignant tumors (up to 10% higher), including glioblastoma, but was negated after accounting for demographic/socioeconomic differences. Conclusions We present the first report suggesting increased non-malignant brain tumor incidence in regions with high particulate and radon exposure. These findings provide insight into unexplained variation in tumor incidence. Future studies are needed to validate these findings in other populations.
Gastrointestinal Stromal Tumors Mimicking Gynecologic Disease: Clinicopathological Analysis of 20 Cases
Liu, Ying , Shahi, Maryam , Miller, Karin, Meyer, Christian F. , Hung, Chien‐Fu , Wu, T.‐C. , Vang, Russell , Xing, Deyin

Mayo Clinic

Diagnostics | June 27, 2022 | Volume: 12 | Issue: 7 | Pages: 1563

10.3390/diagnostics12071563 | PMID 35885469 Get It

Diagnosis of pelvic gastrointestinal stromal tumors (GISTs) can be challenging because of their nonspecific presentation and similarity to gynecological neoplasms. In this series, we describe the clinicopathological features of 20 GIST cases: 18 patients presented with pelvic mass and/or abdominal pain concerning gynecological disease; 2 patients presented with a posterior rectovaginal mass or an anorectal mass. Total abdominal hysterectomy and/or salpingo-oophorectomy (unilateral or bilateral) were performed in 13 cases. Gross and histological examination revealed that the ovary/ovaries were involved in three cases, the uterus in two cases, the vagina in two cases and the broad ligament in one case. Immunohistochemically, all tumors (20/20, 100%) were diffusely immunoreactive for c-KIT. The tumor cells were also diffusely positive for DOG-1 (10/10, 100%) and displayed focal to diffuse positivity for CD34 (11/12, 92%). Desmin was focally and weakly expressed in 1 of the 14 tested tumors (1/14, 7%), whereas 2 of 8 tumors (2/8, 25%) showed focal SMA positivity. At the molecular level, 7 of 8 (87.5%) GISTs with molecular analysis contained c-KIT mutations with the second and third c-KIT mutations detected in some recurrent tumors. In addition to c-KIT mutation, a pathogenic RB1 mutation was detected in two cases. We extensively discussed these cases focusing on their differential diagnosis described by the submitting pathologists during consultation. Our study emphasizes the importance of precision diagnosis of GISTs. Alertness to this entity in unusual locations, in combination with clinical history, morphological features as well as immunophenotype, is crucial in leading to a definitive classification.
The diagnostic criteria of pityriasis rosea and Gianotti-Crosti syndrome – a protocol to establish diagnostic criteria of skin diseases
Chuh, Antonio , Zawar, Vijay , Sciallis, GF, Lee, A

Mayo Clinic

Journal of the Royal College of Physicians of Edinburgh | June 27, 2022 | Volume: 45 | Issue: 3 | Pages: 218-225

10.4997/jrcpe.2015.310a Get It

Cross talk between lysine methyltransferase Smyd2 and TGF-β-Smad3 signaling promotes renal fibrosis in autosomal dominant polycystic kidney disease
Li, Xiaoyan , Agborbesong, Ewud , Zhang, Xiaoqin , Zhou, Julie , Li, Linda Xiaoyan , Zhou, Julie Xia, Li, Xiaogang , Zhang, Lu , Li, Xiaogang

Mayo Clinic

American Journal of Physiology-Renal Physiology | June 27, 2022 | Volume: 323 | Issue: 2 | Pages: F227-F242

10.1152/ajprenal.00452.2021 | PMID 35759739 Get It

Here, we identified a cross talk between SET and MYND domain-containing lysine methyltransferase 2 (Smyd2) and transforming growth factor (TGF)-β-Smad3 signaling and a synergistic feedback loop between them, in which TGF-β stimulates expression of Smyd2 in a Smad3-dependent manner, and upregulation of Smyd2 regulates the transcription of TGF-β and other fibrotic marker genes through direct binding on their promoters or methylating histone H3 indirectly to regulate the transcription of those genes in fibroblasts. Thus, the Smyd2-TGF-β-Smad3-Smyd2 signaling axis plays an important role in promoting renal fibrosis, and targeting Smyd2 with its specific inhibitor should not only delay cyst growth but also ameliorate renal fibrosis in ADPKD.
Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)
Du, Lili, Hoskin, Tanya L. , Anurag, Meenakshi , Cynthia, X. , Bedrosian, Isabelle , Hunt, Kelly K. , Ellis, Matthew J. , Symmans, W. Fraser , Du, Lili , Hoskin, Tanya , Anurag, Meenakshi , Ma, Cynthia , Bedrosian, Isabelle , Hunt, KK , Ellis, Matthew J , Symmans, W Fraser , Suman, Vera J.

Mayo Clinic

Clinical Cancer Research | June 27, 2022 | Volume: 28 | Issue: 15 | Pages: 3287-3295

10.1158/1078-0432.ccr-22-0068 | PMID 35653124 Get It

Abstract Purpose: To evaluate prediction of response and event-free survival (EFS) following neoadjuvant endocrine therapy by SET2,3 index of nonproliferation gene expression related to estrogen and progesterone receptors adjusted for baseline prognosis. Experimental Design: A correlative study was conducted of SET2,3 measured from gene expression profiles of diagnostic tumor (Agilent microarrays) in 379 women with cStage II–III breast cancer from the American College of Surgeons Oncology Group Z1031 neoadjuvant aromatase inhibitor trial SET2,3 was dichotomized using the previously published cutoff. Fisher exact test was used to assess the association between SET2,3 and low proliferation at week 2–4 [Ki67 ≤ 10% or complete cell-cycle arrest (CCCA; Ki67 ≤ 2.7%)] and PEPI-0 rate in cohort B, and the association between SET2,3 and ypStage 0/I in all patients. Cox models were used to assess EFS with respect to SET2,3 excluding cohort B patients who switched to chemotherapy. Results: Patients with high SET2,3 had higher rate of pharmacodynamic response than patients with low SET2,3 (Ki67 ≤ 10% in 88.2% vs. 56.9%, P < 0.0001; CCCA in 50.0% vs. 26.2%, P = 0.0054), but rate of ypStage 0/I (24.0% vs. 20.4%, P = 0.4580) or PEPI = 0 (28.4% vs. 20.6%, P = 0.3419) was not different. Patients with high SET2,3 had longer EFS than patients with low SET2,3 (HR, 0.52, 95% confidence interval: 0.34–0.80; P = 0.0026). Conclusions: This exploratory analysis of Z1031 data demonstrated a higher rate of pharmacodynamic suppression of proliferation and longer EFS in high SET2,3 disease relative to low SET2,3 disease. The ypStage 0/I rate and PEPI = 0 rate were similar with respect to SET2,3.
Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer
Fasching, Peter A. , Liu, Duan , Scully, Steve, Ingle, James N. , Lyra, Paulo C. , Rack, Brigitte , Hein, Alexander , Ekici, Arif B. , Reis, André , Schneeweiß, Andreas , Tesch, Hans , Heinrich, Georg, Beckmann, Matthias W. , Ruebner, Matthias , Huebner, Hanna , Lambrechts, Diether , Madden, Ebony , Shen, Jess, Romm, Jane, Doheny, Kim, Jenkins, Gregory D. , Cunningham, Julie M. , Janni, Wolfgang , Schaid, Daniel J. , Häberle, Lothar , Weinshilboum, Richard M. , Wang, Liewei , Lambrechts, Diether , Lambrechts, Diether , Li, Liang , Fridley, Brooke L , Cunningham, Julie M , Janni, Wolfgang , Monteiro, Alvaro N , Ingle, J , Lambrechts, Diether , Hein, Alexander , Ekici, Arif B , Reis, André , Morais Lyra, Paulo Cilas , Liu, Duan , Fehm, Tanja , Carlson, Erin E. , Li, Liang , Fridley, Brooke L. , Monteiro, Álvaro N.A. , Weinshilboum, Richard M.

Mayo Clinic

Clinical Cancer Research | June 27, 2022 | Volume: 28 | Issue: 15 | Pages: 3342-3355

10.1158/1078-0432.ccr-20-4774 | PMID 35653140 Get It

Abstract Purpose: To identify molecular predictors of grade 3/4 neutropenic or leukopenic events (NLE) after chemotherapy using a genome-wide association study (GWAS). Experimental Design: A GWAS was performed on patients in the phase III chemotherapy study SUCCESS-A (n = 3,322). Genotyping was done using the Illumina HumanOmniExpress-12v1 array. Findings were functionally validated with cell culture models and the genotypes and gene expression of possible causative genes were correlated with clinical treatment response and prognostic outcomes. Results: One locus on chromosome 16 (rs4784750; NLRC5; P = 1.56E-8) and another locus on chromosome 13 (rs16972207; TNFSF13B; P = 3.42E-8) were identified at a genome-wide significance level. Functional validation revealed that expression of these two genes is altered by genotype-dependent and chemotherapy-dependent activity of two transcription factors. Genotypes also showed an association with disease-free survival in patients with an NLE. Conclusions: Two loci in NLRC5 and TNFSF13B are associated with NLEs. The involvement of the MHC I regulator NLRC5 implies the possible involvement of immuno-oncological pathways.
A Global Survey on the Utilization of Cryotherapy and Compression Therapy for the Prevention of Chemotherapy-Induced Peripheral Neuropathy
Chan, Alexandre , Elsayed, Amna, Ng, Ding Quan , Ruddy, Kathryn J. , Loprinzi, Charles L. , Lustberg, Maryam B.

Mayo Clinic

No container title available | June 27, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1757410/v1 Get It

Abstract Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect that is highly prevalent among cancer patients undergoing chemotherapy. There is a growing use of cryotherapy (CryTx) and compression therapy (ComTx) to prevent CIPN at cancer centers worldwide. In this study, we examined the awareness and recommendation of these modalities and evaluated factors associated with awareness. In addition, we investigated the type of technology utilized, barriers to implementation, and perceived adverse events of CryTx and ComTx.Methods: Active members of the Multinational Association of Supportive Care of Cancer (MASCC) were invited to complete an electronic survey that was sent via SurveyMonkey between September to October 2021. The survey assessed participants’ awareness, recommendation, usage, barriers to utilization, and perceived adverse events of CryTx and ComTx. Descriptive statistics and multiple logistic regression were utilized to analyze findings.Results: Out of 184 participants, 70.1% were physicians, 73.4% had over 10 years of practice, and 49.5% were practicing in an outpatient setting. While more than half (63.3%) of participants indicated awareness of CryTx for taxane-induced peripheral neuropathy, less than a quarter (22.8%) indicated recommendation in their practice setting. Factors associated with higher awareness of CryTx for patients receiving taxanes include living in Europe (OR=2.69, 95% CI [1.28-5.64], p=0.009), not practicing in an inpatient setting (OR=3.15, 95% CI [1.45-6.85], p=0.004), and self-identifying as non-physician (OR=2.40, 95% CI [1.03-4.37], p=0.041). Commercial cooling (31.5%) and compression (16.8%) gloves and socks were the most used modalities for CryTx and ComTx, respectively. The most identified barriers to CryTx and ComTx utilization include insufficient evidence (53.5%), logistics (34.8%), and patient discomfort (23.4%). Redness/irritation of skin (27.7%) and numbness/tingling (24.5%) accounted for about half of the perceived adverse events associated with use of CryTx and ComTx. Conclusion: Results of our global survey illustrated that there are varying modes in the delivery of CryTx and ComTx among cancer centers around the world. Education of the utilization of CryTx and ComTx, in addition to efficacy and implementation studies, are needed to close the gap between awareness and implementation in clinical practice.
Factors involved in applicant interview selection and ranking for chronic pain medicine fellowship
Francio, Vinicius Tieppo , Gill, Benjamin , Hagedorn, Jonathan M. , Pagan‐Rosado, Robert , Pritzlaff, Scott , Furnish, Timothy , Kohan, Lynn , Sayed, Dawood , Tieppo Francio, Vinicius , Hagedorn, Jonathan M

Mayo Clinic

Regional Anesthesia & Pain Medicine | June 27, 2022 | Volume: 47 | Issue: 10 | Pages: 592-597

10.1136/rapm-2022-103538 | PMID 35760514 Get It

Introduction Applicants to chronic pain medicine fellowship programs often express confusion regarding the importance of various selection criteria. This study sought to elucidate program directors’ considerations in applicant selection for fellowship interviews and ranking and to correlate these criteria with match statistics to provide a guide for prospective candidates. Methods An electronic survey was sent to all Accreditation Council for Graduate Medical Education-accredited chronic pain fellowship directors. The importance of various applicant characteristics were evaluated and compared with recent match data. Results Fifty-seven program directors completed the survey. The most important factors involved in applicant interview selection were perceived commitment to the specialty, letters of recommendation from pain faculty, scholarly activities, and leadership experiences. Although completion of a pain rotation was valued highly, experience with procedures was of relatively low importance. There was no preference if rotations were completed within the responders’ department. Variability was noted when considering internal applicants or the applicant’s geographic location. When citing main factors in ranking applicants, interpersonal skills, interview impression and applicant’s fit within the institution were highly ranked by most responders. Discussion Assessment of an applicant’s commitment to chronic pain is challenging. Most responders prioritize the applicant’s commitment to chronic pain as a specialty, scholarly activity, participation in chronic pain rotations, pain-related conferences and letters of recommendation from pain faculty. Chronic pain medicine fellowship candidates should establish a progressive pattern of genuine interest and involvement within the specialty during residency training to optimize their fellowship match potential.
Surgical Site Infections after Spinal Surgery in a Tropical Area: A Prospective Monocentric Observational Study
Severyns, Mathieu , Hostalrich, François-Xavier, Vendeuvre, Tanguy , Germaneau, Arnaud , Turmel, Jean-Marie , Cabie, André , El-Fegoun, Abdelkrim Benchikh, Flurin, Laure

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | June 27, 2022 | Volume: 107 | Issue: 2 | Pages: 457-462

10.4269/ajtmh.21-1329 | PMID 35895422 Get It

ABSTRACT. To date, no study has described the microbiological profile of surgical site infections (SSIs) after spine surgery in a tropical environment. The main objective of this study is to describe the microbiology and the risk factors of SSI after spinal surgery in a tropical climate. Our hypothesis is that the microbiology of SSIs in tropical areas is different to what is mainly described in temperate countries. As a consequence, the recommendation for antibiotic prophylaxis administered in the operative room, which mainly relays on the literature, might not be adequate in such countries. We included 323 consecutive patients who underwent a spinal intervention between 2017 and 2019, with a 2-year minimum follow-up. Objective ISO criteria were established in accordance with the criteria accepted by the Center of Disease Control in Atlanta. The identification of risk factors for SSI was carried out by uni- and multivariate analysis with a significance threshold of P < 0.05. The incidence of SSI was 7.7%. A total of 54.8% were in favor of a predominantly digestive origin of germs with an average of 1.68 bacteria found by ISO. Inadequate antibiotic prophylaxis was found in 54.8%. Age and body mass index were found to be independent risk factors for SSI. We report here an unusual microbiological profile of SSI with a predominance of gram-negative bacteria and a low proportion of Staphylococcus aureus and Staphylococcus epidermidis.
User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial
Melnick, Edward R. , Nath, Bidisha , Dziura, James , Casey, Martin F. , Jeffery, Molly M. , Paek, Hyung , Soares, William E. , Hoppe, Jason , Rajeevan, Haseena , Skains, Rachel M. , Patel, Mehul D, Chari, Srihari V , Platts‐Mills, Timothy F. , D’Onofrio, Gail , Jeffery, Molly Moore , Melnick, Edward R , Skains, Rachel M , Li, Fangyong , Walter, Lauren A. , Patel, Mehul D, Hess, Erik P.

Mayo Clinic

BMJ | June 27, 2022 | Volume: 377 | Issue: No issue available | Pages: e069271

10.1136/bmj-2021-069271 | PMID 35760423 Get It

Abstract Objective To determine the effect of a user centered clinical decision support tool versus usual care on rates of initiation of buprenorphine in the routine emergency care of individuals with opioid use disorder. Design Pragmatic cluster randomized controlled trial (EMBED). Setting 18 emergency department clusters across five healthcare systems in five states representing the north east, south east, and western regions of the US, ranging from community hospitals to tertiary care centers, using either the Epic or Cerner electronic health record platform. Participants 599 attending emergency physicians caring for 5047 adult patients presenting with opioid use disorder. Intervention A user centered, physician facing clinical decision support system seamlessly integrated into user workflows in the electronic health record to support initiating buprenorphine in the emergency department by helping clinicians to diagnose opioid use disorder, assess the severity of withdrawal, motivate patients to accept treatment, and complete electronic health record tasks by automating clinical and after visit documentation, order entry, prescribing, and referral. Main outcome measures Rate of initiation of buprenorphine (administration or prescription of buprenorphine) in the emergency department among patients with opioid use disorder. Secondary implementation outcomes were measured with the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) framework. Results 1 413 693 visits to the emergency department (775 873 in the intervention arm and 637 820 in the usual care arm) from November 2019 to May 2021 were assessed for eligibility, resulting in 5047 patients with opioid use disorder (2787 intervention arm, 2260 usual care arm) under the care of 599 attending physicians (340 intervention arm, 259 usual care arm) for analysis. Buprenorphine was initiated in 347 (12.5%) patients in the intervention arm and in 271 (12.0%) patients in the usual care arm (adjusted generalized estimating equations odds ratio 1.22, 95% confidence interval 0.61 to 2.43, P=0.58). Buprenorphine was initiated at least once by 151 (44.4%) physicians in the intervention arm and by 88 (34.0%) in the usual care arm (1.83, 1.16 to 2.89, P=0.01). Conclusions User centered clinical decision support did not increase patient level rates of initiating buprenorphine in the emergency department. Although streamlining and automating electronic health record workflows can potentially increase adoption of complex, unfamiliar evidence based practices, more interventions are needed to look at other barriers to the treatment of addiction and increase the rate of initiating buprenorphine in the emergency department in patients with opioid use disorder. Trial registration ClinicalTrials.gov NCT03658642 .